Skip to content
Review Open access

Epigenetic memory of epithelial–mesenchymal transition: linking transient plasticity to metastasis, therapy resistance, and immune evasion

Aug 2026 · Cellular Oncology · 0 citations

TL;DR

It is argued that metastatic competence, therapy resistance, and immune evasion can be viewed as functional outputs of remembered plasticity rather than solely as consequences of a contemporaneous mesenchymal phenotype, positioning memory-bearing states as an important target for future therapeutic strategies.

Abstract

Epithelial–mesenchymal transition (EMT) is increasingly recognized as a dynamic, plastic process that equips tumor cells with invasive capacity, stress tolerance, stem-like features, and adaptability, contributing to metastasis, therapeutic failure, and immune escape. Accumulating evidence indicates that these effects can outlast the inducing signal: tumor cells may retain molecular and functional traces of prior EMT exposure, biasing future cell-state behavior. This Review terms this phenomenon EMT memory. We propose EMT memory as a conceptual framework distinguishing it from EMT induction and maintenance through its persistence after signal withdrawal, its capacity to alter future cellular responsiveness, and, in its strongest form, its transmissibility across cell division. DNA methylation and chromatin-state remodeling emerge as the most plausible core substrates, reinforced by histone dynamics, chromatin remodelers, and noncoding RNA networks that stabilize post-EMT states. Temporal concepts including hysteresis, reversibility windows, and partial EMT stabilization clarify when transient plasticity becomes durably encoded, helping explain why highly aggressive tumor cells are often not fully mesenchymal yet remain strongly metastatic, drug tolerant, and immune evasive. We argue that metastatic competence, therapy resistance, and immune evasion can be viewed as functional outputs of remembered plasticity rather than solely as consequences of a contemporaneous mesenchymal phenotype. If transient EMT can be consolidated into persistent adaptive states, therapeutically relevant vulnerabilities may lie not only in EMT-inducing pathways, but also in the mechanisms that encode, reinforce, and preserve EMT memory—positioning memory-bearing states as an important target for future therapeutic strategies.

Read PDF

Similar papers

Review Open access Aug 2026

Oncofetal reprogramming and cellular plasticity in colorectal cancer: from mechanisms to clinical translation

The conceptual boundaries and operational criteria for identifying OnF in CRC are discussed, its regulatory mechanisms, plasticity-associated phenotypes, and translational relevance are examined, and the importance of distinguishing direct evidence of OnF from evidence of related plasticity mechanisms is emphasized.

Hao-Yu Wang, Song-Hao Liu, Ming-Xuan Zhang et al. · 0 citations
Review Open access Aug 2026

Epithelial–mesenchymal transition in carcinoma: navigating phenotypic states to target resistance and metastasis

The clinical translation of EMT-directed interventions faces steep methodological hurdles, primarily driven by unverified causal dynamics and unresolved therapeutic safety profiles, and will require dynamic, multi-pronged strategies tailored to specific carcinoma cell states and spatial niches.

Xuecong Wang, C. Zhang, Yi Zhao et al. · 0 citations
Review Open access Aug 2026

Epigenetic reprogramming of lineage switching in cancer.

This review evaluating how the antagonistic interplay between Polycomb and Trithorax complexes, chromatin modifier activity, and enhancer reprogramming affects lineage identity and enables multi-lineage plasticity in cancer underscores epigenetic deregulation as a primary driver of lineage plasticity and intratumoral heterogeneity.

Ezgi Boyvatlı, Burcu Akman, E. Bağırsakçı et al. · 0 citations
Review Open access Aug 2026

Role of epithelial-mesenchymal transition (EMT) in malignancies: current status and future prospects

Unraveling the intricate mechanisms of EMT activation in cancer will contribute to the advancement of personalized medicine and the design of more effective treatments against metastatic disease and pave the way for advancements in personalized medicine and improved treatment strategies for patients affected by EMT-related conditions.

Vafa Meftahpour, T. C. Dakal, Jarek Maciaczyk et al. · 0 citations
Review Open access Jul 2026

Beyond EMT: Mesenchymal drift as an emerging driver of stromal-immune reprogramming in prostate cancer

By integrating diverse mesenchymal transition processes under a unified conceptual framework, this review positions mesenchymal drift as a unifying axis of stromal-immune reprogramming in prostate cancer and underscores its significance for next-generation therapeutic strategies.

Zijia Zhang, Feifan Liu, Shuze Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.